‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on the chop­ping block

If you dig in­to the small print on Roche’s Q1 re­port out Wednes­day, you’ll find sev­er­al high pro­file mid- and late-stage set­backs for its ex­per­i­men­tal drugs in the pipeline.

First up is RG7388 idasanut­lin, where Roche not­ed that its 440-pa­tient Phase III in re­lapsed and re­frac­to­ry AML — dubbed Mir­ros — failed the pri­ma­ry end­point. The tri­al of the MDM2 in­hibitor was axed from the pipeline track­er, along with a Phase II for poly­cythemia ve­ra, which was termed a pipeline pri­or­i­ti­za­tion de­ci­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.